RxDoctor Payments Data

Cynthia Frey

Acute Care · Cincinnati, OHNPI 1659501625

Payments from drug & device makers

$1,513in general payments, 2019–2025

Across 68 payments — averaging $22.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$420
  • Pfizer$158
  • Boehringer Ingelheim$124
  • Boston Scientific$112
  • Merck$106
  • Novartis$83
  • plus $510 from 13 others

What the payments were for

  • Food & beverage$1,513100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,513 in reported general payments places this provider in the 80th percentile of 1,101 acute care providers in Ohio.

See all acute care providers in Ohio

Medicare billing

Part B allowed, 2024
$44,170
Medicare patients
295
Services billed
664

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban116$117,609
XareltoRivaroxaban50$46,505
EntrestoSacubitril/Valsartan23$20,820
JardianceEmpagliflozin15$16,024
BrilintaTicagrelor13$14,458
Flecainide Acetate46$1,980
Metoprolol Succinate196$1,575
Torsemide40$750
Amiodarone Hcl42$623
ClopidogrelClopidogrel Bisulfate96$558
Atorvastatin Calcium71$542
Furosemide88$360
Hydralazine Hcl43$360
Spironolactone43$312
Carvedilol48$301

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$158$117,609116 claims
Johnson & JohnsonXarelto$69$46,50550 claims
NovartisEntresto$83$20,82023 claims
Boehringer IngelheimJardiance$124$16,02415 claims
AstraZenecaBrilinta$69$14,45813 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,101 acute care providers in Ohio.

Other acute care in Cincinnati

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →